Tag: Vitrakvi

April 13, 2022 Off

Bayer receives approval for precision oncology treatment Vitrakvi in China

By Author

The Center of Drug Evaluation (CDE) of China‚Äôs National Medical Products Administration (NMPA) approved Bayer’s larotrectinib, under the brand name Vitrakvi, for the treatment of adult and pediatric patients with advanced solid tumors that harbor a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. NTRK gene fusions should be identified by a sufficiently validated test.